Navigation Links
Five-Year Follow-Up Data on CERAMENT™|BONE VOID FILLER Demonstrates Long-Term Safety and Long-Lasting Bone Mineral Density Improvement in Osteoporotic Patients
Date:10/28/2013

Lund, Sweden (PRWEB) October 28, 2013

BONESUPPORT AB, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced results from a five-year follow-up study on patients treated with CERAMENT™|BONE VOID FILLER, as presented at the Combined Orthopaedic Research Society (CORS) meeting in Venice, Italy. The study demonstrates long-term safety and long-lasting bone mineral density improvement, following bone remodeling after treatment with CERAMENT™|BONE VOID FILLER in osteoporotic patients.

“The study results confirm what we know to be true about CERAMENT™, its osteoconductive characteristics create a stable framework to support new bone growth, making it a safe and effective solution to filling voids such as correction osteotomies following malunited distal radius fractures,” said Professor Magnus Tägil, lead investigator in the study. “More importantly, the full bone remodeling seen within a year after CERAMENT™ treatment seems to be a long-lasting solution because the normalized bone mineral density persists at least for five years, as demonstrated in the present study.”

The aim of the study was to evaluate the long-term performance of CERAMENT™|BONE VOID FILLER in correction osteotomy following malunited distal radius fractures, a common complication after this fracture. Most often, an iliac crest bone graft is used to fill the void, however, this method is associated with a high incidence rate of donor site morbidity.

“We believe CERAMENT™|BONE VOID FILLER offers significant advantages over current treatment methods and we are pleased to see the positive outcomes demonstrated in this study,” said Lloyd Diamond, CEO of BONESUPPORT. “Studies such as this help improve and advance medical care and help health care decision makers direct resources to the strategies and treatments that work best.”

About BONESUPPORT

BONESUPPORT is an emerging leader of injectable bone graft substitutes for orthopedic trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENT™ is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENT’s unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENT™|G is the first CE-marked injectable antibiotic eluting ceramic bone graft substitute. CERAMENT™|G is indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections) in CE marked countries. CERAMENT™|G is not available in the United States.

CERAMENT™ is a fully developed product platform that is commercially available in the U.S. and Europe and is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT spans more than eleven years. Over forty-five pre-clinical, clinical and animal studies have been conducted and more than 6,000 patients have been treated with CERAMENT. The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT, please visit http://www.bonesupport.com.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11272027.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill
2. Study examines benefit of follow-up CT when abdominal ultrasound inconclusive
3. 6 month follow-up of patients with benign MRI-guided breast biopsies may not be necessary
4. Medical follow-up in celiac disease is less than optimal
5. Missing Follow-Up Colonoscopies Could Raise Colon Cancer Risk
6. A Viagra follow-up? Drug used to treat glaucoma actually grows human hair
7. Less than half of youth with mental illness received adequate follow-up care, new study finds
8. 5-year follow-up - over half of all ACL reconstructions could be avoided
9. Evidence shows concussions require long-term follow-up for players
10. Follow-Up Care After Chest Pain Called Crucial
11. Chernobyl follow-up study finds high survival rate among young thyroid cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 million people living with ... worldwide. On Sunday, June 5, 2016, communities around the world will gather to recognize ... , National Cancer Survivors Day® is an annual worldwide Celebration of Life that is ...
(Date:5/26/2016)... ... May 26, 2016 , ... In an effort to provide hair restoration information to the ... users and those who do not use the app. Dr. Mohebi, the founder of Parsa ... Dr. Mohebi Live . , Dr. Mohebi says, “The positive response to the Snapchat ...
(Date:5/26/2016)... ... 26, 2016 , ... North Cypress Medical Center hosted its 9th ... Cypress. With the help of community partners, the event organizers raised $45,000 for the ... wounded service members and their families through health, wellness, and therapeutic support. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, a ... first PowerWave Instructor Certification Course in Stoughton, Massachusetts. The course was led by ... through the 8 hour interactive course to qualify participants as certified PowerWave trainers. ...
(Date:5/26/2016)... ... May 26, 2016 , ... The introduction of our professional athletes coincides ... HEAD ™”. , “We are proud to introduce Meghan Klingenberg, defender and ... have Brian Quick, wide receiver for Los Angeles who was a second round selection ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... -- According to market research "Global Insulin ... Forecast to 2022 - Industry Insights by Type (Insulin ... P&S Market Research, the global insulin delivery device market ... is expected to grow at a CAGR of 6.6% ... is expected to witness the fastest growth at a ...
(Date:5/25/2016)... England , May 25, 2016 ... company employing the precision of circulating tumour DNA ... today announces the appointment of Professor Clive ... provide medical leadership across the clinical development programme, ... Inivata,s products help deliver significant improvements in clinical ...
(Date:5/24/2016)... 24, 2016   , ... in overall bowel cleansing and superiority in ... leansing of the ascending ... , Norgine B.V. today announced new positive data from ... ascorbate bowel preparation) versus standard 2 litre PEG with ascorbate. The ...
Breaking Medicine Technology: